new_0222_0453|VERA|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0453|VERA|Long Name|1|1|Vera Therapeutics Inc Total Current Assets (Quarterly) (USD)|Vera Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Vera Therapeutics Inc Inventories (Quarterly) (USD)|Vera Therapeutics Inc Net PP&E (Quarterly) (USD)|Vera Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Vera Therapeutics Inc Total Liabilities (Quarterly) (USD)|Vera Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Vera Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Vera Therapeutics Inc Total Deposits (Quarterly) (USD)|Vera Therapeutics Inc Book Value (Quarterly) (USD)|Vera Therapeutics Inc Retained Earnings (Quarterly) (USD)|Vera Therapeutics Inc Treasury Stock (Quarterly) (USD)|Vera Therapeutics Inc EV to Revenues|Vera Therapeutics Inc EV to Earnings|Vera Therapeutics Inc EV to Free Cash Flow|Vera Therapeutics Inc EV to Assets (Quarterly)|Vera Therapeutics Inc PS Ratio|Vera Therapeutics Inc PE Ratio|Vera Therapeutics Inc Price to Book Value|Vera Therapeutics Inc PEG Ratio|Vera Therapeutics Inc Debt to Equity Ratio|Vera Therapeutics Inc Dividend Yield|Vera Therapeutics Inc Shareholder Yield (TTM)|Vera Therapeutics Inc Percent of Shares Outstanding Short|Vera Therapeutics Inc Total Receivables (Quarterly) (USD)|Vera Therapeutics Inc Total Payables (Quarterly) (USD)|Vera Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Vera Therapeutics Inc Return on Invested Capital|Vera Therapeutics Inc Quality Ratio Score|Vera Therapeutics Inc Momentum Score|Vera Therapeutics Inc Beta (1Y)|Vera Therapeutics Inc Sustainable Growth Rate (TTM)|Vera Therapeutics Inc Institutional Investor Ownership Percentage|Vera Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Vera Therapeutics Inc Total Employees (Annual)|Vera Therapeutics Inc EPS Diluted (Quarterly) (USD)|Vera Therapeutics Inc SG&A Expense (Quarterly) (USD)|Vera Therapeutics Inc Shares Outstanding|Vera Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Vera Therapeutics Inc Ordinary Shares Number (Quarterly)|Vera Therapeutics Inc Payout Ratio|Vera Therapeutics Inc Quick Ratio (Quarterly)|Vera Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Vera Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Vera Therapeutics Inc Effective Tax Rate (TTM)|Vera Therapeutics Inc Return on Equity|Vera Therapeutics Inc Net Income (TTM) (USD)|Vera Therapeutics Inc Revenue (TTM) (USD)|Vera Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Vera Therapeutics Inc Revenue (Quarterly) (USD)|Vera Therapeutics Inc Gross Profit (Quarterly) (USD)|Vera Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Vera Therapeutics Inc Net Income (Quarterly) (USD)|Vera Therapeutics Inc Net Interest Income (Quarterly) (USD)|Vera Therapeutics Inc Price (USD)|Vera Therapeutics Inc Total Return Price (USD)|Vera Therapeutics Inc Enterprise Value (USD)|Vera Therapeutics Inc 30-Day Average Daily Volume|Vera Therapeutics Inc 1 Year Price Returns (Daily)|Vera Therapeutics Inc Short Interest|Vera Therapeutics Inc PE Ratio (Forward)|Vera Therapeutics Inc PE Ratio (Forward 1y)|Vera Therapeutics Inc PS Ratio (Forward)|Vera Therapeutics Inc PS Ratio (Forward 1y)|Vera Therapeutics Inc Quarterly EPS Estimates (USD)|Vera Therapeutics Inc Quarterly Revenue Estimates (USD)|Vera Therapeutics Inc Quarterly EPS Surprise|Vera Therapeutics Inc Quarterly Revenue Surprise|Vera Therapeutics Inc Quarterly Actual EPS (USD)|Vera Therapeutics Inc Quarterly Actual Revenue (USD)|Vera Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Vera Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Vera Therapeutics Inc Price Target (USD)|Vera Therapeutics Inc Consensus Recommendation|Vera Therapeutics Inc Price Target Num Estimates|Vera Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Vera Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Vera Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Vera Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Vera Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Vera Therapeutics Inc Land and Improvements (Quarterly) (USD)|Vera Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Vera Therapeutics Inc Other Properties (Quarterly) (USD)|Vera Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0453|VERA|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0453|VERA||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0453|VERA||5|5|91|91|0|0|0|91|91|91|0|91|91|0|0|0|1.44329896907|0|0|0|1.43827160494|0|0|1.44329896907|0|15.4117647059|91|91|91|0|0|0|0|0|30.625|91.3333333333|91|91.3333333333|91.3333333333|22.125|0|91|0|0|91.3333333333|91.4|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|1.44329896907|1.44329896907|1.44329896907|1.44242424242|0|15.4117647059|0|0|0|0|0|91.4285714286|0|0|0|91.5|25.8571428571|25.8571428571|21.8181818182|12.6315789474|21.8181818182|0|0|91.3333333333|91.3333333333|91.3333333333|0|0|0|0
new_0222_0453|VERA||6|6|3|3|0|0|0|3|3|3|0|3|3|0|0|0|194|0|0|0|162|0|0|194|0|17|3|3|3|0|0|0|0|0|8|6|3|6|6|8|0|3|0|0|6|5|0|0|3|0|0|0|0|6|6|6|194|194|194|165|0|17|0|0|0|0|0|7|0|0|0|2|7|7|11|19|11|0|0|6|6|6|0|0|0|0
new_0222_0453|VERA||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0453|VERA|202003|202003|202003||||||||||||||||||||||||||||||||||4.0763||-0.6069|1.032||||||-0.6069|||||||||-2.474|-2.474|0.044||||||||||||||||||||||||1.439|0.108|0.024||||
new_0222_0453|VERA|202006|202006|202006||||||||||||||||||||||||||||||||||4.0763||-0.8841|1.219||||||-0.8841|0||||||||-3.604|-3.604|-0.062||||||||||||||||||||||||1.954|0.112|0.063||||
new_0222_0453|VERA|202009|202009|202009||||||||||||||||||||||||||||||||||4.0763||-1.0941|0.652||||||-0.7467|0||||||||-4.46|-4.46|-0.064||||||||||||||||||||||||1.969|0.673|0.064||||
new_0222_0453|VERA|202012|202012|202012|54.261|53.654||0||143.902|2.406|141.496||-89.348|-91.447||||||||||||||0.052|0.909|0|||||||4.0763|29|-10.518|1.136|||20.4793|||-10.1304||||-53.413|||||-42.874|-42.875|-0.013||||||||||||||||||||||||39.844|-0.642|0.015||||
new_0222_0453|VERA|202103|202103|202103|51.532|49.505||||145.141|3.753|141.388||-93.316|-96.161||||||||||||||0|1.739|0|||||||20.4793|12|-0.2302|1.784|||20.4793|||-0.2302||||-55.653|||||-4.714|-4.714|0.002||||||||||||0||||0||||||||2.932|0.035|0||||
new_0222_0453|VERA|202105|202103|202103|||||||||||||||-8.6012|||||||0||0.0366|||||||||53.0334|||||21.1318|||||||||||||||||17.25|17.25|315.0186|||7729||||||||||||||||||||||||
new_0222_0453|VERA|202106|202106|202106|95.876|91.625||||5.492|3.771|1.721||92.155|-99.598||||-4.5781||||3.0616|||0||0.0331|0|2.44|0.021||||||86.8433|10.4999|13|-0.33|2.614|21.2776||21.2776|||-0.5595|-51.176|||-55.486|||||-3.437|-3.437|0.002|13.26|13.26|190.516|59493.6667||7042||||||0||||0|0|0|26|1|2|||3.235|0.05|0||||
new_0222_0453|VERA|202107|202106|202106|||||||||||||||-7.0016||||4.156|||0||0.0477|||||||||86.4725||||||||||||||||||||||18|18|291.3718|15541.6667||10156||||||||||||||||||||||||
new_0222_0453|VERA|202108|202106|202106|||||||||||||||-5.3348||||3.4033|||0||0.0147|||||||||86.9772|||||21.2776|||||||||||||||||14.74|14.74|222.0068|11967.3||3123|||||||||||0|0||1||||||||||
new_0222_0453|VERA|202109|202109|202109|89.76|86.191||||5.69|4.042|1.648||85.477|-107.209||||-6.3374||||4.3189|||0||0.5221|0|1.958|0.021||||||96.203|21.2655|9|-0.36|3.688|21.2776||21.2776|||-0.3429|0|||-58.637|||||-7.611|-7.611|0.005|17.35|17.35|282.9754|117415.3667||111089||||||0||||0|0|0|26|1|2|||3.564|0.059|0||||
new_0222_0453|VERA|202110|202109|202109|||||||||||||||-7.2904||||4.8168|||0||0.8701|||||||||96.0508||||||||||||||||||||||19.35|19.35|325.5306|65189||185137|||||||||||0|0|26|1|2|||||||||
new_0222_0453|VERA|202111|202109|202109|||||||||||||||-15.1292||||8.9116|||0||0.3729|||||||||96.5712|||||21.2776|||||||||||||||||35.8|35.8|675.5471|38268.6667||79354|||||||||||0|0|26|1|2|||||||||
new_0222_0453|VERA|202112|202112|202112|||||||||||||||-10.8023||||6.6514|||0||1.1405|||||||||98.6898||||||||||||||||||||||26.72|26.72|482.3465|81156.6333||242675||||||0|||||0|0|32.5|1|2|||||||||
new_0222_0453|VERA|202201|202112|202112|||||||||||||||-7.5668||||4.9611|||0||1.6863|||||||||98.6611||||||||||||||||||||||19.93|19.93|337.8716|79796.9||358803|||||||||||||32.5|1|2|||||||||
new_0222_0453|VERA|202202|202112|202112|||||||||||||||-8.4769||||5.4366|||0|||||||||||||||||||||||||||||||||21.84|21.84|378.5118|116084|||||||||||||||32.5|1|2|||||||||
new_0222_0453|VERA|202203|202203|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0453|VERA|202206|202206|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0453|VERA|202209|202209|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0453|VERA|202212|202212|202212||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||